Mania Clinical Trial
Official title:
A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania
To compare the time to response, response rates, remission rates, and side effects in Bipolar Disorder inpatients treated with Depakote ER or Depakote DR for acute mania or mixed mania.
Status | Completed |
Enrollment | 5 |
Est. completion date | September 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Males and females between the ages 19-65 (inclusive). - DSM-IV diagnosis of acute mania or acute mixed mania . Exclusion Criteria: - DSM-IV diagnoses of bipolar disorder, depressed type, bipolar disorder rapid cycling type, major depressive disorder with psychotic features, schizoaffective disorder, schizophrenia, substance use disorder (active use within the last 3 months), or organic mood disorder. - History of a seizure disorder or an unstable physical disorder judged to significantly affect central nervous system function. - Female subjects who are pregnant or of childbearing potential who are not using medically accepted means of contraception and female patients who are breastfeeding. - Subjects who require antipsychotic medications because of severe psychosis and /or agitation. - Subjects on antidepressants or mood stabilizers including lithium, oxcarbazepine, carbamazepine, and lamotrigine. - Subjects who have failed previous trials with Depakote DR or Depakote ER. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Abbott |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Young Mania Rating Scale (YMRS)will be used daily for the first week and then every three day to assess the severity of mania. | study duration | ||
Primary | The Clinical Global Impression Scale (CGI) will be used daily for teh first week then every 3 days to assess overall functioning. | study duration | ||
Primary | The Udvalg for Kliniske Undersogeiser (UKU) Side Effect Rating Scale will be administered at base line and weekly for the remainder of the study to determine the medication side effect profiles. | study duration | ||
Secondary | The Montgomery-Asberg Depression Rating Scale will be performed daily for the first week and weekly thereafter to assess for any emergent symptoms of depression. | study duration | ||
Secondary | The Brief Psychiatric Rating Scale (BPRS) will be performed daily for the first week and weekly thereafter to assess for any emergent symptoms of psychosis. | study duration | ||
Secondary | The Drug Attitude Inventory (DAI-10)will measure subjects' attitudes towards medications at the screen and final visit. | study duration | ||
Secondary | The Schizophrenia Quality of Life Scale (SQLS)will measure subjects' quality of life at the screen and final visit. | study duration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT00534222 -
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
|
N/A | |
Completed |
NCT00140179 -
Valnoctamide in Mania
|
Phase 3 | |
Completed |
NCT01237379 -
Peroxisomal Defects and Familial Risk for Bipolar Disorder
|
N/A | |
Completed |
NCT01315028 -
Bipolar Intervention Study: Cognitive Interpersonal Therapy
|
N/A | |
Completed |
NCT00254488 -
Treatment of Bipolar Mania in Older Adults
|
Phase 4 | |
Completed |
NCT00560079 -
Efficacy of Allopurinol and Dypiridamole in Acute Mania
|
Phase 4 | |
Completed |
NCT00518947 -
Pharmacotherapy of Treatment-Resistant Mania
|
Phase 3 | |
Recruiting |
NCT05444907 -
Deep Brain Stimulation-Induced Mania in Parkinson's Disease
|
||
Enrolling by invitation |
NCT02360267 -
Pediatric Bipolar Registry
|
||
Completed |
NCT01092221 -
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode
|
Phase 3 | |
Completed |
NCT00521365 -
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
|
Phase 4 | |
Completed |
NCT01191918 -
The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania
|
Phase 4 | |
Completed |
NCT01541605 -
Methylphenidate for the Treatment of Acute Mania
|
Phase 3 | |
Completed |
NCT00893581 -
Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
|
N/A | |
Completed |
NCT00208195 -
Depakote ER Therapy for Mania Comorbid With Substance Abuse
|
Phase 4 | |
Completed |
NCT00181922 -
Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
|
Phase 4 | |
Completed |
NCT00181935 -
Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder
|
Phase 4 | |
Active, not recruiting |
NCT05703711 -
Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa
|
N/A | |
Completed |
NCT00917501 -
Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania
|
Phase 2 |